Drug Profile
Research programme: p38 MAP kinase inhibitors - Novartis
Alternative Names: p38 MAP kinase inhibitors research programme - NovartisLatest Information Update: 14 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 14 Jul 2010 Discontinued - Preclinical for Inflammation in Europe (unspecified route)
- 09 Dec 2004 Preclinical trials in Inflammation in Europe (unspecified route)